HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion
EORTC 2334-BTG
Phase 2 small_molecule active
Quick answer
HYDROXYCARBAMIDE , BEVACIZUMAB , SUNITINIB , OCTREOTIDE , EVEROLIMUS , Lutathera 370 MBq/mL solution for infusion for Recurrent Meningioma without local treatment options (Surgery or Radiotherapy) is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Recurrent Meningioma without local treatment options (Surgery or Radiotherapy)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active